Development of sulfasalazine-associated drug-induced lupus erythematosus in patient with rheumatoid arthritis (clinical case)
Drug-induced lupus syndrome (DLS) is o rore adverse event with o variety of drugs. More thon o hundred of drugs ore known thot con couse the development of DLS, ond this list is growing os new drugs oppeor. Physicians of ony specialty con foce such complications of theropy ond should be owore of this pathology. The article presents on analysis of o clinical cose of DLS development ogoinst the background of long-term administration of sulfasalazine in a patient with a reliable diagnosis of rheumatoid arthritis, as well as a literature review, which includes data on the prevalence, drug groups, clinical manifestations, diagnosis ond treatment of this pathology.